Dr. Max C. Kim, MD
Ophthalmology (Glaucoma Specialist (Ophthalmology) Physician)
20940 N Tatum Blvd, Suite 250
Phoenix, AZ 85050
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Nevada School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,259
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Nevada School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Glaucoma Specialist (Ophthalmology) Physician primary
AZ license 35715 -
Ophthalmology Physician
AZ license 35715
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 1,259
- Services billed
- 7,169
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,187 | 963 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,179 | 739 |
| Exam of the internal drainage system of eye | 865 | 852 |
| Imaging of optic nerve | 851 | 820 |
| Exam of visual field with extended testing | 842 | 808 |
| Imaging of retina | 707 | 641 |
| Photography of the retina | 625 | 620 |
| New patient office or other outpatient visit, 45-59 minutes | 138 | 138 |
| Ultrasound scan of cornea to determine thickness | 126 | 126 |
| Laser repair to improve eye fluid flow | 122 | 91 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Phoenix, AZ | 1,149 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Phoenix, AZ | 931 |
| Timolol Maleate Other prescribers in Phoenix, AZ | 496 |
| Lumigan (bimatoprost) Other prescribers in Phoenix, AZ | 452 |
| Dorzolamide Hcl Other prescribers in Phoenix, AZ | 363 |
| Brimonidine Tartrate Other prescribers in Phoenix, AZ | 263 |
| Rhopressa (netarsudil mesylate) | 257 |
| Prednisolone Acetate Other prescribers in Phoenix, AZ | 180 |
| Alphagan P (brimonidine tartrate) Other prescribers in Phoenix, AZ | 164 |
| Travoprost Other prescribers in Phoenix, AZ | 109 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 59 payments worth $1,612 in total to this clinician.
| Glaukos Corporation | $432 |
|---|---|
| AbbVie Inc. | $361 |
| Alcon Vision LLC | $283 |
| Bausch & Lomb Americas Inc. | $124 |
| Apellis Pharmaceuticals, Inc. | $107 |
| Sun Pharmaceutical Industries Inc. | $104 |
| Dompe US, Inc. | $95.30 |
| Thea Pharma Inc. | $72.17 |
| Food and Beverage | $1,612 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $7,189 in research payments for these studies, mostly to the institutions running them.
- Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie Inc. · Completed · NCT03891446 - Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.